[{"id":"208e94c5-11e1-4e2c-881a-18ba9d9acb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06620302","created_at":"2025-02-25T15:15:08.184Z","updated_at":"2025-02-25T15:15:08.184Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","source_id_and_acronym":"NCT06620302","lead_sponsor":"Children's Oncology Group","biomarkers":" BCL2 • DNAJB1 • PRKACA","pipe":"","alterations":" ","tags":["BCL2 • DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • DT2216"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/20/2025","start_date":" 03/20/2025","primary_txt":" Primary completion: 12/30/2031","primary_completion_date":" 12/30/2031","study_txt":" Completion: 12/30/2031","study_completion_date":" 12/30/2031","last_update_posted":"2025-02-13"}]